Oncology News

INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference....

EVANSTON, Ill.--(BUSINESS WIRE)--Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced the appointment of Venkat R. Krishnamurthy, Ph.D., as Chief Scientific Officer. Dr. Krishnamurthy is an accomplished scientific and executive leader with more than 15 years of experience developing RNA therapeutics, bringing deep expertise in oligonucleotide chemistry, drug delivery, and advancing genetic medicine programs from discovery through c...

DUBLIN--(BUSINESS WIRE)--The "Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions" has been added to ResearchAndMarkets.com's offering. The peptide therapeutics market is poised for significant growth, projected to escalate from USD 84.2 billion in 2023 to USD 162.4 billion by 2035, marking a CAGR of 6.8%. These therapeutics, built from polypeptides, are increasingl...

SACRAMENTO, Calif.--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D-Suisun City) for introducing legislation to ensure equitable access to required diagnostic and supplemental breast imaging, by eliminating the financial barriers patients face in accessing needed breast cancer screening. The exorbitant out-of-pocket costs associated with this critical breast imaging, ranging from hundreds to thousands of dollars, often forc...

PLYMOUTH, Minn.--(BUSINESS WIRE)--VizMark Secures FDA 510k clearance for VM1 Visual Tumor Marker, Advancing Precision in Breast Cancer Imaging...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Global Market Report 2025" has been added to ResearchAndMarkets.com's offering. The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.9%. This growth has been fueled by the rising incidence of cancer globally, increased healthcare spending, demand for targeted treatmen...

SAN FRANCISCO--(BUSINESS WIRE)--iSono Health, a pioneer in women’s health imaging, today announced the commercial launch of ATUSA™, an FDA-cleared, wearable, and automated 3D quantitative breast ultrasound platform. Designed to bring high-quality imaging into everyday clinics, ATUSA™ unlocks the $14B U.S. breast imaging market by eliminating reliance on hard-to-find skilled sonographers and cost-prohibitive equipment. A graduate of Y Combinator and the Texas Medical Center Accelerator, iSono He...

LOS ANGELES--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) today announced that Howard R. Soule, Ph.D., will retire as PCF’s Chief Science Officer, Executive Vice President, and Lori and Michael Milken Chair at the end of March 2026. For nearly three decades, Dr. Soule’s visionary leadership of PCF’s prestigious and high-impact programs to advance prostate cancer research and treatments has helped improve and extend the lives of countless patients with prostate cancer, helping drive the...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA® (nogapendekin alfa inbakicept) for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy. This marks the first approval of the C...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease. This regulatory action by the SFDA adds to the existing approvals in the Uni...